This report evaluates the clinical utility of liquid biopsy tests for colorectal cancer (CRC) screening to reduce CRC morbidity and mortality.
Precision Medicine
The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
- Will testing change patient management for this indication?
- If so, what tests and/or therapies should I use?
- Should we cover testing and/or therapies?
- Can we manage these services internally?
- Precision Therapy Assessment
- Clinical Utility Evaluation
- Laboratory Test Insights
- Molecular Test Assessment
- Germline Rapid Reports
- Precision Medicine Research Briefs
FilmArray Respiratory Panel 2 (BioFire Diagnostics LLC)
This report evaluates the analytical validity, clinical validity, and clinical utility of the FilmArray Respiratory Panel 2.
Envisia Genomic Classifier (Veracyte)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Envisia Genomic Classifier.
Pharmacogenetic Testing to Guide Codeine or Tramadol Prescribing for Pain in Pediatric Patients
This report evaluates the clinical utility of pharmacogenetic testing for CYP2D6 gene variants prior to prescribing codeine or tramadol to improve opioid treatment–related outcomes in pediatric patients with organic causes of pain.
Pharmacogenetic and Pharmacogenomic Testing for Opioid Treatment for Pain in Adults – Selected Single-Gene Variants and Pharmacogenomic Panels
This report evaluates the clinical utility of pharmacogenetic testing for:
-
CYP2D6 gene variants prior to prescribing codeine or tramadol
-
Single-gene variants in the CYP2D6, CYP3A…
Prenatal and Preimplantation Genetic Testing for Risk of Hearing Loss
This report evaluates the
Pharmacogenetic Testing for Opioid Treatment for Pain – OPRM1 and COMT Variants
This report evaluates the clinical utility of pharmacogenetic testing for OPRM1 and/or COMT gene variants to improve opioid treatment–related outcomes in patients with organic causes of pain.
Genetic Screening of Newborns for Risk of Hearing Loss
This report evaluates the clinical utility of genetic screening of newborns for risk of hearing loss.
MI Profile (Caris Life Sciences)
This report evaluates the analytical validity, clinical validity, and clinical utility of the MI Profile test.
MI Profile (Caris Life Sciences)
This report evaluates the analytical validity, clinical validity, and clinical utility of the MI Profile test.